Sarfraz Humaira, Anand Kartik, Liu Shujuan, Shah Shilpan
Department of Internal Medicine, Houston Methodist, Houston, TX 77030, USA.
Equal contribution.
Ecancermedicalscience. 2020 Feb 20;14:1012. doi: 10.3332/ecancer.2020.1012. eCollection 2020.
Multiple myeloma (MM) is the second most common haematological malignancy in the USA. MM has been linked to various autoimmune disorders in many studies; one systemic review even suggested an increased risk of MM among patients with autoimmune disorders. MM is associated with many haematological, rheumatologic and neurological conditions. A few case reports suggest that MM can be associated with immune thrombocytopenic purpura (ITP), although this is rare. We present a case of MM with concurrent ITP which was refractory of steroids and intravenous immunoglobulin but had a response with anti-neoplastic therapy for MM. We also review all the cases of ITP with MM described in the literature. If conventional treatment for ITP associated with MM fails to improve platelet count, anti-neoplastic therapy for MM should be considered.
多发性骨髓瘤(MM)是美国第二常见的血液系统恶性肿瘤。许多研究已将MM与各种自身免疫性疾病联系起来;一项系统评价甚至表明自身免疫性疾病患者患MM的风险增加。MM与许多血液学、风湿病学和神经学疾病相关。一些病例报告表明MM可能与免疫性血小板减少性紫癜(ITP)有关,尽管这种情况很罕见。我们报告一例并发ITP的MM病例,该病例对类固醇和静脉注射免疫球蛋白治疗无效,但对抗骨髓瘤治疗有反应。我们还回顾了文献中描述的所有MM合并ITP病例。如果与MM相关的ITP的常规治疗未能提高血小板计数,则应考虑对抗骨髓瘤进行治疗。